Drug intelligence / Profile preview

Ovasital-F

Development stage: Unknown
Lead developer: Liveon Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Ovasital-F is an oral dietary supplement developed by Liveon Healthcare for the management of Polycystic Ovary Syndrome (PCOS). It features a combination of Myo-inositol and D-chiro-inositol, typically in a 40:1 ratio, which mimics the physiological plasma ratio. These inositol isomers function as second messengers in the insulin signaling pathway, helping to alleviate insulin resistance, lower androgen levels, and restore regular menstrual cycles and ovulation. The formulation also includes Folic acid to support DNA synthesis and provide essential prenatal nutrition. It is marketed as a non-hormonal approach to improving metabolic and reproductive outcomes in women with PCOS.

Brand names: Ovasital-F

Targets

INSR (Insulin receptor)DHFR (Dihydrofolate reductase)

Beyond the preview

Go deeper on Ovasital-F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ovasital-F.

Explore the full profile